Clinical trials: Ritonavir
Infection, Human Immunodeficiency Virus I
Study Of Chemokine Coreceptor 5 (CCR5) Antagonist GW873140 In R5-Tropic Treatment-Experienced HIV-Infected Subjects
The purpose of this study is to evaluate the safety and efficacy of the CCR5 antagonist GW873140 or placebo in combination with an optimized background regimen in treatment-experienced HIV-infected subjects with R5-tropic virus
- Trial name
- NCT00197145
- Testing
- GW873140
- Where
- 55 sites in United States, Canada and 1 more
- Volunteers
- 24 people
- Sponsor
- ViiV Healthcare
COVID - 19
Early-stage Trial to Determine a Safe and Effective Dose for Ratutrelvir in Patients With Mild to Moderate COVID-19
This is an Early-stage Clinical Trial to Determine a Safe and Effective Dose for Ratutrelvir in Patients With Mild to Moderate COVID-19. It will also learn about the safety of drug Ratutrelvir.
- Trial name
- NCT07157007
- Testing
- Ratutrelvir (83-0060) non-randomised, Paxlovid, Ratutrelvir (83-0060)
- Where
- 15 sites in Australia, South Korea and 2 more
- Volunteers
- 90 people
- Sponsor
- Traws Pharma, Inc.
Infection, Human Immunodeficiency Virus
A Study To Assess GW433908 (Fosamprenavir) Containing Regimens In HIV-1 Infected Subjects
GW433908 (fosamprenavir; FPV)is a pro-drug of amprenavir (APV) which is more water soluble and can be formulated into a tablet with a reduced pill burden (four 700mg tablets of FPV versus sixteen 150mg capsules daily for APV.
- Trial name
- NCT00296504
- Testing
- fosamprenavir (GW433908), ritonavir
- Where
- 24 sites in United States, Brazil and 6 more
- Volunteers
- 753 people
- Sponsor
- ViiV Healthcare
HIV Infections
Differences Between Women and Men Taking a Combination of Indinavir, Ritonavir, Enteric-Coated Didanosine, and Stavudine Who Previously Took Anti-HIV Drugs
The purpose of this study is to see how safe and effective it is to give multi-drug treatment with indinavir (IDV) plus ritonavir (RTV) plus enteric-coated didanosine (ddI) plus stavudine (d4T) and if there are differences in…
- Trial name
- NCT00006397
- Testing
- Indinavir sulfate, Ritonavir, Stavudine
- Where
- 15 sites in United States, Puerto Rico
- Volunteers
- 200 people
- Sponsor
- PPD Development, LP
HIV Infections
Bioequivalence Study of Atazanavir 300 mg Capsule
The purpose of this clinical research study is to assess the bioequivalence of atazanavir administered as a single 300 mg capsule relative to two atazanavir 150 mg capsules in healthy subjects.
- Trial name
- NCT00393328
- Testing
- Atazanavir + Ritonavir
- Where
- United States
- Volunteers
- 46 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
Healthy Volunteer
A Study of RO5190591 (Danoprevir) in Healthy Volunteers
This non-randomized, open-label study will evaluate the interaction of RO5190591(danoprevir)/ritonavir with and without ketoconazole and the safety and tolerability in healthy volunteers.
- Trial name
- NCT01164488
- Testing
- danoprevir, ketoconazole, ritonavir
- Where
- United States
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Hoffmann-La Roche
HIV Infections
TMC114-C227: A Study to Evaluate the Effectiveness and Safety of TMC114 (Darunavir) With a Low Dose of Ritonavir as Monotherapy (no Other Anti-HIV Drugs Will be Given) in Patients Who Have Never Been Treated With Antiretrovirals (Anti-HIV Drugs) Previously
This is an open label study (no placebos are used; all patients will receive the true medication) to evaluate the effectiveness of TMC114/rtv in treatment naÃ-ve (never previously received anti-HIV drugs), HIV 1 infected patients.
- Trial name
- NCT00513513
- Testing
- TMC114 (darunavir) / ritonavir
- Volunteers
- 7 people
- Sponsor
- Tibotec Pharmaceuticals, Ireland
HIV Infections
Atazanavir and Ritonavir (ATV/RTV) and an Oral Contraceptive in Healthy Females
The purpose of this study is to administer a combined oral contraceptive (ethinyl estradiol and norgestimate) with the HIV treatment of atazanavir and ritonavir to healthy females in order to assess if the concentrations of the…
- Trial name
- NCT00357604
- Testing
- Ortho Tri-Cyclen (ethinyl estradiol + norgestimate), Ortho Tri-Cyclen LO (ethinyl estradiol + norgestimate) + Atazanavir/Ritonavir for 14 days then Ortho Tri-Cyclen for 7 days
- Where
- United States
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
HIV Infections
A Study to Compare Two Anti-HIV Drug Combinations
The purpose of this study is to compare 2 anti-HIV drug combinations.
- Trial name
- NCT00002447
- Testing
- Ritonavir, Efavirenz, Saquinavir
- Where
- 26 sites in United States, Canada and 1 more
- Volunteers
- 146 people
- Sponsor
- Hoffmann-La Roche
Human Immunodeficiency Virus-Type 1
A Study to Assess the Safety and Effectiveness of Darunavir for Treating Human Immunodeficiency Virus-Type I (HIV-1) Infection in Filipino Patients
The purpose of this study is to assess the safety and effectiveness of darunavir for the treatment human immunodeficiency virus-type I (HIV-1) infection among Filipino adults.
- Trial name
- NCT01726348
- Testing
- No intervention
- Sponsor
- Janssen Pharmaceutica
Pharmacokinetics
Drug-Drug Interaction Between Colchicine and Ritonavir
Ritonavir is a potent inhibitor of CYP3A4, one of the enzymes responsible for the metabolism of colchicine. This study will evaluate the effect of multiple doses of ritonavir on the pharmacokinetic profile of a single 0.6 mg dose…
- Trial name
- NCT00983515
- Testing
- Colchicine, Ritonavir
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Mutual Pharmaceutical Company, Inc.
Human Papilloma Virus (HPV), High-risk Human Papillomavirus Infection
A Study of the Preliminary Efficacy of DARE-HPV to Treat High-risk Persistent Human Papillomavirus (hrHPV)
The goal of this clinical study is to learn if DARE-HPV can treat persistent high-risk human papillomavirus (hrHPV). The primary outcome will be if the genital infection clears following treatment in 30, 60 or 90 days.
- Trial name
- NCT07601074
- Testing
- Lopinavir / ritonavir
- Where
- 10 sites in United States
- Volunteers
- 118 people
- Sponsor
- Daré Bioscience, Inc.
Human Immunodeficiency Virus
Evaluation of Kaletra Therapy Over the Long-term
Long term observation of patients under lopinavir/ritonavir containing therapy
- Trial name
- NCT01083810
- Testing
- Lopinavir/Ritonavir (Kaletra)
- Where
- 90 sites in Germany
- Volunteers
- 284 people
- Sponsor
- Abbott
Human Immunodeficiency Virus 1
A Study to Compare Brachial Artery Reactivity and Cardiovascular Risk of a Treatment Simplification by Darunavir/Ritonavir (DRV/r) 800/100 mg Versus a Triple Combination Therapy Containing DRV/r in HIV-1 Infected Patients
The purpose of this study is to compare change of brachial artery flow mediated vasodilatation using Darunavir/Ritonavir (DRV/r) 800/100 mg once daily as a monotherapy (use of a single medication) versus a triple combination…
- Trial name
- MONARCH (NCT01391013)
- Testing
- Darunavir(DRV), Ritonavir, 2 nucleoside reverse transcriptase inhibitors (NRTIs)
- Volunteers
- 30 people
- Sponsor
- Janssen-Cilag S.p.A.
Coronavirus Disease 2019 (COVID-19)
A Study to Learn About the Study Medicine Paxlovid (Nirmatrelvir + Ritonavir) in Adults Aged 60 and Older Living in Korean Long-term Care Hospitals Who Have COVID-19
The purpose of this study is to learn about the effects of the study medicine (called Paxlovid) for the possible treatment of COVID-19 in older adults who live in long-term care hospitals (LTCHs) in Korea.
- Trial name
- NCT07089680
- Testing
- Nirmatrelvir/Ritonavir
- Where
- 7 sites in South Korea
- Volunteers
- 937 people
- Sponsor
- Pfizer
HIV Infections
The Safety and Effectiveness of Indinavir Plus Ritonavir Plus Two NRTIs in HIV-Infected Patients Who Need Early Intervention Treatment
The purpose of this study is to see if it is safe and effective to give indinavir plus ritonavir plus 2 NRTIs to HIV-infected patients who need early intervention treatment.
- Trial name
- NCT00005118
- Testing
- Indinavir sulfate, Ritonavir
- Where
- 40 sites in United States
- Volunteers
- 100 people
- Sponsor
- Merck Sharp & Dohme LLC
Chronic Hepatitis C
Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C - An Observational Study in Austria (REAL)
The study seeks to provide evidence of the effectiveness and obtain patient reported outcome (PRO) and work productivity data of the interferon-free ABBVIE REGIMEN (ombitasvir/paritaprevir/ritonavir +/- dasabuvir) +/- Ribavirin…
- Trial name
- REAL (NCT02582658)
- Volunteers
- 173 people
- Sponsor
- AbbVie
Infection, Human Immunodeficiency Virus I, HIV-1 Infection
A Dose Ranging Study Of GW640385 Boosted With Ritonavir (Rtv) In Comparison To A RTV-Boosted Protease Inhibitor (PI) In HIV-1 Infected PI-Experienced Adults
This is a two phase study (randomised and non-randomised phase). The randomised phase will initially examine 4 blinded doses of GW640385 boosted with rtv (with continuation of current background therapy) in comparison to an…
- Trial name
- NCT00242879
- Testing
- Physician determined comparator PI + ritonavir, GW640385 + ritonavir
- Where
- 70 sites in United States, Australia and 9 more
- Volunteers
- 130 people
- Sponsor
- ViiV Healthcare
Chronic Hepatitis B
The Safety, Antiviral Activity, and Pharmacokinetics of Morphothiadine Mesilate Capsules
The Safety, Antiviral Activity, and pharmacokinetics of Morphothiadine Mesilate Capsules/Ritonavir Tablets in Patients with Chronic Hepatitis B
- Trial name
- NCT03638076
- Testing
- GLS4, RTV
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Sunshine Lake Pharma Co., Ltd.
Infection, Human Immunodeficiency Virus I, HIV Infection
GW640385 Plus Ritonavir And NRTIs For 48 Weeks In HIV-1 Infected Adults
This is a proof of concept (POC) single arm study of GW640385, a protease inhibitor, in combination with RTV and 2 or more nucleoside reverse transcriptase inhibitors (NRTI) backbone.
- Trial name
- NCT00257621
- Testing
- GW640385, Ritonavir
- Where
- 9 sites in United States
- Volunteers
- 30 people
- Sponsor
- ViiV Healthcare